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Electroacupuncture (EA) has been reported to have beneficial effects on Alzheimer’s
disease (AD). BACE1 (β-site amyloid precursor protein-cleaving enzyme 1) is involved in
the abnormal production of amyloid-β plaque (Aβ), a hallmark of AD pathophysiology.
Thus, the present study investigated the effects of EA on memory impairment, Aβ
production, and BACE1 expression in senescence-accelerated mouse prone 8 (SAMP8)
mice. We found that EA improved spatial learning and memory impairment of SAMP8
mice. Furthermore, EA attenuated Aβ production and repressed the expression of BACE1
in the hippocampus of SAMP8 mice. Taken together, our results suggest that EA could
have a potential therapeutic application in AD and that BACE1may be an important target
of EA in the treatment of AD.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by two neu-
ropathological hallmarks: extracellular senile plaque deposits, composed of amyloid β-peptide (Aβ),
and intracellular neurofibrillary tangles. Ample evidence indicates that Aβ plays a central role in
AD pathogenesis (Hardy and Selkoe, 2002; Selkoe and Schenk, 2003; Zhang and Xu, 2007). Aβ is
generated after the cleavage of amyloid precursor protein (APP) by the β-secretase [β-site amyloid
precursor protein-cleaving enzyme 1 (BACE1), β-site APP cleaving enzyme 1], and γ-secretase
complex (Hardy and Selkoe, 2002). In addition, BACE1 expression and activity levels are increased
in AD brains and correlate with specific regions affected by Aβ deposition (Fukumoto et al., 2002;
Holsinger et al., 2002; Li et al., 2004; Harada et al., 2006; Coulson et al., 2010). Targeting BACE1 with
small interfering RNA (siRNA) and BACE1 gene deletion reduces Aβ levels and prevents learning
and memory impairment in a mouse model of AD (Ohno et al., 2004; Singer et al., 2005). Thus,
BACE1 is considered a promising target for prevention or modification of AD (Li et al., 2006;
Menting and Claassen, 2014). Moreover, several BACE1 inhibitors have entered clinical trials (Yan
and Vassar, 2014).
Abbreviations:AD, Alzheimer’s disease; Aβ, amyloid β-peptide; BACE1, β-site amyloid precursor protein-cleaving enzyme 1;
EA, electroacupuncture; ELISA, enzyme-linked immunosorbent assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
MWM, Morris water maze; PGC-1α, peroxisome proliferator-activated receptor-γ co-activator-1α; qRT-PCR, quantita-
tive real-time reverse transcription polymerase chain reaction; SAMP8, senescence-accelerated mouse prone 8; SAMR1,
senescence-accelerated-resistant mouse 1; siRNA, small interfering RNA; SIRT1, Sirtuin 1.
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The senescence-accelerated mouse prone 8 (SAMP8) strain is
a spontaneous animal model of accelerated aging. SAMP8 mice
exhibit cognitive and behavioral alterations and neuropathologi-
cal abnormalities observed in patients with AD, such as deficits in
learning andmemory, Aβ deposits, and tau phosphorylation (Pal-
las et al., 2008; Takeda, 2009; Manich et al., 2011). Thus, SAMP8
mice have been proposed as an excellent model for exploring the
pathophysiological mechanism of sporadic AD and a plausible
experimental model for developing preventative and therapeutic
treatments for late-onset/age-related AD, which accounts for the
vast majority of cases in humans (Cheng et al., 2014; Bayod et al.,
2015). Senescence-accelerated resistant mouse 1 (SAMR1), which
has a genetic background similar to that of SAMP8, does not
exhibit these senescence-related neuronal phenotypes and has
been used extensively as a control strain (Takeda, 1999, 2009).
In addition, BACE1 protein levels and activity were increased in
SAMP8 mice compared with age-matched SAMR1 mice (Zhou
et al., 2012; Orejana et al., 2015).
Acupuncture penetrates the skin with needles and stimulates
specific points on the body. It has long been used for the treat-
ment of many diseases. Electroacupuncture (EA) is a reforma-
tive form of traditional acupuncture that is accepted by Western
countries due to its reproducibility (Chon and Lee, 2013). EA
or acupuncture has been shown to improve cognitive deficits
in animal models of AD (Cheng et al., 2008; Li et al., 2012,
2014; Wang et al., 2014a). Moreover, acupuncture activates spe-
cific cognitive-related regions and enhances hippocampal connec-
tivity in AD patients (Wang et al., 2012, 2014c). Our previous
studies demonstrated that EA at Dazhui (GV14) and Shenshu
(BL23) in SAMP8 mice improves cognitive deficits, activates
AMP-activated protein kinase (AMPK), and upregulates Sirtuin
1 (SIRT1)-dependent peroxisome proliferator- activated receptor-
γ co-activator-1α (PGC-1α) expression (Dong et al., 2015). A
recent study showed that the SIRT1-PPARγ-PGC-1 pathway may
regulate BACE1 expression under metabolic stress conditions
(Wang et al., 2013). Both activation of the SIRT1 signaling path-
way and PGC-1α overexpression attenuate BACE1 expression
and Aβ levels (Katsouri et al., 2011; Marwarha et al., 2014). On
the basis of these studies, we speculate that EA may reduce the
expression BACE1 and consequently reduces Aβ levels.
In this study, we evaluated the effects of EA on spatial learning
andmemory impairment in SAMP8mice. Furthermore, we exam-
ined the effects of EA on Aβ production and BACE1 expression.
Materials and Methods
Animals and Groups
This study utilized 32 male SAMP8 mice and 16 male homolo-
gous SAMR1 mice (7months of age), which are provided by the
Department of Laboratory Animal Science of Peking University.
There was no difference between their baseline ages. All mice
were housed under standard conditions at 22 2°C and a 12 h
light/dark cycle with free access to food and water throughout the
entire study. The mice were randomly assigned to the following
three groups (n= 16/group): SAMR1 normal control group (Rc),
SAMP8 control group (Pc), and SAMP8 EA group (Pe). Mice in
the Pe group received EA administration, whilemice in the Rc and
Pc groups were grasped for the same amount of time and with the
same extent of strength asmice in the Pe group.Moreover, mice in
the Rc and Pc groups were restrained in nets for the same length
of time as mice in the Pe group. All experimental procedures
were approved by the Ethical Committee of Fujian University of
Traditional Chinese Medicine and were performed according to
the internationally accepted principles for laboratory animal use
and care. We made all efforts to minimize the animal suffering in
the study.
EA Treatment
Electroacupuncture treatment was performed as described in our
previous study (Dong et al., 2015). Briefly, we used nets to fix the
mice by the assistant’s hands during the entire treatment. Three
stainless steel acupuncture needles of 0.25mm in diameter were
inserted at a depth of approximately 5mm into the “Dazhui”
acupoint (GV14, below the spinous process of the seventh cervi-
cal vertebra) and the bilateral “Shenshu” acupoint (BL23, at the
depression lateral to the lower border of the spinous process of
the second lumbar vertebra). The acupoint location in the mouse
is mainly in accordance with the transpositional method, which
locates the animal acupoints on the surface of the animal’s skin,
corresponding to the anatomical site of the human acupoint. Thus,
the anatomical site and location of Dazhui in both humans and
mice are the same, and are located below the spinous process
of the seventh cervical vertebra. Shenshu in humans is located
1.5 cun lateral to the lower border of the spinous process of
the second lumbar vertebra. On the basis of the transpositional
method, Shenshu in a mouse is located at the depression lateral
to the lower border of the spinous process of the second lumbar
vertebra.Needles atGV14 and the sideBL23were connected to the
output terminals of the EA instrument (Hwato, model No. SDZ-
V, Suzhou Medical Instruments Co., Ltd., Suzhou, China) and
bilateral BL23 was alternated. We performed continuous-wave
stimulation at a frequency of 2Hz (intensity 1mA). An individual
EA session was administered daily for 20min, for 8 days, with
2 days of rest, for a period of 30 days. Each treatment for all the
mice has been performed at the same day and the same time point
during EA treatment.
Morris Water Maze Test
At the end of the 30 days of EA treatment, mice were tested for
spatial learning and memory in the Morris water maze (MWM).
The apparatus consisted of a large circle tank (120 cm in diameter,
30 cm in height) and was filled with opaque water (21–23°C) with
white milk. The pool was divided into four quadrants of equal
area. A platform (10 cm in diameter) was placed 1 cm below the
water surface at the midpoint of one of the four quadrants. The
position of the platform was unchanged during the training ses-
sion. Before the acquisition training session, a visible platform test
was performed, which confirmed that there were no significant
differences in sensory, motor, or motivational activities among
these three groups. Next, a hidden platform test was performed
in succession. The paradigm consisted of four trials per day over
five consecutive days in which the mice were placed at one of
four different start positions for each trial and given 90 s to locate
the hidden platform. In each trial, the escape latency was defined
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as the time a mouse spent from being placed into the water to
finding and climbing onto the hidden platform. If a mouse failed
to locate the platform within 90 s, then it was gently guided onto
the platform and allowed to remain there for 10 s, and its escape
latency was recorded as 90 s. Retention memory was evaluated
on probe trials presented on day 6. During the probe trial, the
platform was removed from the pool. The mice were released into
the water on the opposite side of the target quadrant and were
allowed to swim freely for 60 s. The total number of times that each
mouse crossed the position where the platform was once placed
and the time that it spent in the target quadrant and opposite target
were recorded.
Tissue Collection
At the end of the MWM test, mice were anesthetized intraperi-
toneally (i.p.) with 10% chloral hydrate (100 g/0.35mL) and
immediately perfused transcardially with 50mL of phosphate-
buffered saline (PBS). The brains were immediately removed and
the hippocampi were then isolated, frozen on powdered dry ice,
and stored at 80°C until further assay.
Western Blotting Analysis
Frozen hippocampi were homogenized in RIPA buffer sup-
plemented with protease inhibitor cocktail and centrifuged at
12,000 g for 20min at 4°C. The supernatants were collected,
and total protein levels were quantified using a BCA protein assay
kit (Beyotime, Haimen, Jiangsu, China). Equal amounts (30µg)
of each sample were separated on 10% SDS-polyacrylamide gels.
After electrophoresis, the proteins were transferred onto a nitro-
cellulose membrane (Millipore) at 100V for 60min on ice. The
membrane was blocked with 5% w/v non-fat dry milk powder
in Tris-buffered saline with 0.05% Tween 20 (TBS-T) for 1 h.
After blocking, membranes were incubated with the primary
antibodies overnight at 4°C. The following primary antibodies
were used: anti-Aβ (6E10, 1:1000, Covance), rabbit polyclonal
anti-BACE1 (1:1000, Sigma), and anti-β-actin (1:5000, Sigma).
Immunoreactive bands were detected with HRP-conjugated goat
anti-rabbit IgG (1:2000, Santa Cruz Biotechnology). The mem-
brane was washed with TBS-T and the immunocomplex was
visualized using an enhanced chemiluminescence detection kit
(Thermo Scientific, Rockford, IL, USA). Signals of the membrane
were scanned using the FluorChem Scanner and quantified using
NIH Image J software. These results were normalized against β-
actin expression levels and confirmed by triplicate measurements
of the same sample.
Determination of Aβ Levels by Enzyme-Linked
Immunosorbent Assay
For human Aβ1-42 levels detection, frozen hippocampal samples
were homogenized in 5 M guanidine hydrochloride, and cen-
trifuged at 16,000 g for 20min at 4°C. The supernatant was
collected and diluted with dilution buffer plus protease inhibitor
cocktail. Levels of Aβ1-42 were measured using a human Aβ1-
42 Enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen)
according to the manufacturer’s instructions. The absorbance was
read at 450 nm using a 96-well plate reader, and Aβ1-42 levels
were calculated from a standard curve and normalized against
total protein levels, as determined using the BCA protein assay kit.
Quantitative Real-Time Reverse Transcription
Polymerase Chain Reaction
Total RNAwas isolated using the RNeasyMini Kit (Qiagen). Next,
cDNA was synthesized using the TaqMan reverse transcription
reagents kit (Applied Biosystems) and real-time PCR was
performed on a 7300 real-time PCR system (Applied Biosystems,
CA, USA) using the SYBR Green PCR master mix (Applied
Biosystems) according to the manufacturer’s instructions.
The primers used for real-time PCR were the following:
BACE1 forward: 50-CCGGCGGGAGTGGTATTATGAAGT-30,
reverse: 50-GATGGTGATGCGGAAGGACTGATT-30; GAPDH
forward: 50-TGGAAAGCT GTGGCGTGAT-30, reverse: 50-
TGCTTCACCACCTTCTTGAT-30. The data were analyzed
according to the delta–delta Ct (∆∆CT) method and were
normalized against GAPDH expression in each sample.
Statistical Analysis
The results are expressed as the mean SEM. The escape latency
of mice in the MWM test was analyzed using two-way analysis
of variance (ANOVA) for repeated measurement. Tukey’s test was
further used as a post hoc test to detect between-group differ-
ences. One-way ANOVA was employed to analyze other data
obtained in these experiments followed by LSD (equal variances
assumed) or Dunnett’s T3 (equal variances not assumed) for the
post hoc test between groups. P< 0.05 was considered statistically
significant.
Results
Effect of EA on Memory Impairment in SAMP8
Mice in the MWM Test
The MWM test was performed to detect the effect of EA on
spatial learning and memory ability. The escape latency during
acquisition training is shown in Figure 1A. The escape latency in
the hidden platform acquisition phase decreased with an increase
in the training day. Compared to Rc mice, Pc mice exhibited
significantly longer escape latencies in the training session. EA
significantly shortened the escape latency in SAMP8 mice. How-
ever, swimming speed was not significantly different among these
groups (Figure 1B). After the training test, the probe test was per-
formed to analyze the maintenance of memory. Pc mice exhibited
a trend toward decreased time spent in the target quadrant and
opposite quadrant compared with Rc mice, and EA increased the
time spent by SAMP8 mice in the target quadrant and opposite
quadrant (Figures 1C,D). In addition, the number of platform
crossings was significantly reduced in Pc mice compared with
Rc mice, and EA increased the number of platform crossings in
SAMP8 mice (Figure 1E). Taken together, these results indicated
that spatial learning and memory were impaired in SAMP8 mice
and that EA could improve this cognitive impairment.
EA Treatment Inhibits Aβ Production in the
SAMP8 Mouse Hippocampus
To investigate the effects of EA on Aβ production in the SAMP8
mouse brain, we used western blotting analysis for Aβ and ELISA
for Aβ1-42. Western blotting analysis showed that Aβ expression
was increased in the hippocampus of SAMP8 mice compared
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FIGURE 1 | Effects of EA on spatial learning and memory impairment in
SAMP8 mice. (A) Effect of EA on the escape latency of mice during five
consecutive days of the hidden platform test. Pc mice exhibited a longer escape
latency in the training session compared to Rc mice. EA significantly reduced
the escape latency in SAMP8 mice. (B) Histograms showing the swimming
speed during acquisition training. (C) Histograms showing the average swim
time in the target quadrant during the probe test. (D) Histograms showing the
average swim time in the opposite quadrant. (E) Comparisons of the number of
platform crossings in the probe trial. Data are represented as the meanSEM
(n= 14–16). *P<0.05, **P<0.01 versus Pc.
with that of the hippocampus of SAMR1 mice. Furthermore, EA
treatment reduced Aβ expression (Figures 2A,B). In addition,
we analyzed the levels of Aβ1-42 in the hippocampus using
ELISA. Consistent with the results of western blotting analysis,
increased Aβ1-42 levels were observed in the hippocampus in
Pc mice compared with Rc mice. Moreover, Pe mice showed a
significant reduction in the levels of Aβ1-42 compared with Pc
mice (Figure 2C).
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FIGURE 2 | Effects of EA administration on Aβ production in the
SAMP8 mouse hippocampus. (A) Representative western blotting analysis
of Aβ. (B) Quantification of (A) based on densitometry showed that the protein
levels of Aβ were markedly reduced in the Pe mice hippocampus compared
with that of Pc mice hippocampus. β-actin was used as an internal control.
(C) Results of ELISA Aβ1-42 assays showed that EA treatment resulted in a
decrease in Aβ production. The level of Aβ1-42 was standardized against
proteins obtained from hippocampus tissue and is expressed as
Aβ1-42pg/mg of tissue protein. *P<0.05, **P<0.01 versus Pc.
EA Inhibits BACE1 Expression in the SAMP8
Mouse Hippocampus
Because BACE1 is a key enzyme in Aβ generation, reduced levels
of Aβ1-42 may result from decreased biogenesis of BACE1. Thus,
we investigated the effects of EA treatment on BACE1 expression
in SAMP8mice. BACE1 proteinwasmeasured usingwestern blot-
ting analysis.We found that BACE1 expressionwas increased in Pc
mice compared with that of Rc mice and that EA reduced BACE1
protein levels in SAMP8 mice (Figures 3A,B). To define whether
FIGURE 3 | Effects of EA treatment on BACE1 expression in SAMP8
mouse hippocampus. (A) Representative western blotting analysis of
BACE1. (B) Quantitative analysis of the protein expression of BACE1 showed
that the level of BACE1 protein was reduced in Pe mice compared with that of
Pc mice. (C) qRT-PCR was used to measure mRNA levels. BACE1 mRNA
levels were normalized against GAPDH mRNA level and compared with Pc.
*P<0.05, **P<0.01 versus Pc.
changes in BACE1 protein expression were due to alterations in
BACE1 transcription, we further examined BACE1 mRNA lev-
els using quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR). As expected, EA treatment resulted
in a significant decrease in BACE1 mRNA levels compared to Pc
(Figure 3C).
Discussion
The present study demonstrated that EA treatment improves spa-
tial memory in the SAMP8mouse model of AD. Furthermore, we
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have shown that EA treatment reduces Aβ production and BACE1
expression in the hippocampus of SAMP8mice. Our data support
that EA is effective for the treatment of AD in animal models.
It has been reported that compared with age-matched SAMR1
mice, cognitive impairment of SAMP8 mice could be detected
beginning at 5months of age and was severe at 7months (Kang
et al., 2014). In addition, from as early as 6months of age, SAMP8
mice show Aβ deposition in the hippocampus that increases in
number and extent with age (Del Valle et al., 2010; Kang et al.,
2014). The tau hyperphosphorylation is significantly increased in
the hippocampus of SAMP8 mice from 7months of age (Jiang
et al., 2015b) compared with SAMR1 mice. Taken together,
SAMP8 mice have developed AD-like behavior and pathological
hallmarks at 7months of age. Moreover, a number of studies
used 7 or 7.5-month-old SAMP8 mice to investigate the effect
of EA and drug treatment on AD (Tan et al., 2014; Jiang et al.,
2015a). Thus, we used SAMP8 mice at 7months of age in this
study. Additionally, Kang et al. have systematically evaluated
the pathologic morphology in the hippocampus of SAMR1 and
SAMP8mice using Nissl staining, immunohistochemical staining
(anti-Aβ antibody), and Golgi staining at different time points
(Kang et al., 2014). Previous studies have shown that acupuncture
reduces neuron loss and increases cell proliferation in the hip-
pocampus of SAMP8 mice (Cheng et al., 2008; Li et al., 2012). On
the basis of these results, our study emphasizes the effect of EA on
Aβ production and BACE1 expression in SAMP8 mice.
Amyloid plaques are one of the characteristic pathological hall-
marks of AD, and the deposition of Aβ is themain cause of plaque
production. Aβ accumulation in the brain results in a cascade
of cellular changes in AD pathogenesis. Thus, Aβ reduction or
clearance from the brainmay be an important therapeutic strategy
for prevention and treatment of AD (Jakob-Roetne and Jacobsen,
2009; Mao et al., 2012). It has been demonstrated Aβ lowering
capacity of anti-Aβ antibodies in transgenic models of AD and in
AD patients (Bohrmann et al., 2012; Ostrowitzki et al., 2012). To
examine the mechanism of EA treatment in AD mice, we inves-
tigated the effects of EA on Aβ expression in the hippocampus
of SAMP8 mice. These results exhibited a significant increase
in Aβ expression in the hippocampus of 8-month-old SAMP8
mice, which was consistent with a previous study showing that
SAMP8 mice demonstrate deposition of Aβ from 6months of
age (Del Valle et al., 2010). EA treatment obviously decreased Aβ
expression. Because Aβ1-42 is more cytotoxic and is more likely
to aggregate and form plaques than Aβ1-40 (Vattemi et al., 2009),
we further examined Aβ1-42 levels using ELISA in our study.
Our results supported that the levels of Aβ1-42 in the hippocam-
pus were significantly increased in SAMP8 mice compared with
SAMR1 mice (Li et al., 2009). In addition, EA treatment reduced
the levels of Aβ1-42 in SAMP8mice. Taken together, these results
suggested that EA treatment might reduce Aβ production.
Aβ, the product of the large type1 trans-membrane protein
APP, is produced in a two-step proteolytic process initiated by
BACE1 and followed by γ-secretase. Thus, BACE1 expression
levels are strongly correlated with Aβ levels. In addition, BACE1
overexpression increases Aβ formation in APP transgenic mice
(Bodendorf et al., 2002), whereas BACE1 knockout mice produce
little or noAβ (Luo et al., 2001), indicating that BACE1 expression
plays a critical role in Aβ biosynthesis. Thus, targeting BACE1 is
the focus of AD research in the prevention of Aβ generation in
AD (Sathya et al., 2012). It has been reported that several BACE1
inhibitors have entered clinical trials (May et al., 2011; Hamada
and Kiso, 2013; Hilpert et al., 2013). However, a recent clinical
trial with a BACE1 inhibitor had to be halted due to liver toxicity
(Lahiri et al., 2014). EA has demonstrated therapeutic potential
for the treatment of AD and has no adverse side effects. Our
results showed that EA improves cognitive deficits in SAMP8
mice, which are consistent with previous studies (Cheng et al.,
2008; Li et al., 2012, 2014;Wang et al., 2014a). In this study, we fur-
ther examined the effects of EA on BACE1 expression in SAMP8
mice. ThemRNA levels and protein levels of BACE1 are increased
in the hippocampus of SAMP8 mice compared with that of the
hippocampus of age-matched SAMR1 mice, which is consistent
with a previous study (Orejana et al., 2015). Furthermore, our
results showed that EA reduces BACE1 expression. It has been
reported that targeting BACE1 with siRNAs reduced Aβ produc-
tion and the neurodegenerative and behavioral deficits in an APP
transgenic mouse model of AD (Singer et al., 2005). Lowering
BACE1 expression reduced the formation of Aβ, thereby prevent-
ing its subsequent aggregation into toxic aggregates (Citron, 2002;
McConlogue et al., 2007). In addition, triptolide and icariin, the
major active components extracted from a traditional Chinese
herb, have been reported to inhibit BACE1 expression, attenuate
Aβ production and deposition, and improve cognitive deficits in
transgenic mouse models of AD (Wang et al., 2014b; Zhang et al.,
2014). Similar to our results, these results support the hypothesis
that reduced BACE1 activity has great therapeutic potential for
the treatment of AD, and BACE1 is a prime therapeutic target for
lowering Aβ levels in AD.
We showed previously that EA activates AMPK expression
and upregulates SIRT1-dependent PGC-1α expression in SAMP8
mice (Dong et al., 2015). Moreover, a recent study has shown that
SIRT1-PPARγ- PGC-1 represses BACE1 transcription andBACE1
protein levels (Wang et al., 2013). In this study, we found that
EA reduced BACE1 mRNA and protein levels and decreased Aβ
levels. On the basis of these data, we proposed that EA upregu-
lates SIRT1-PPARγ- PGC-1, which represses BACE1 expression,
thereby reducing Aβ production and consequently improving
cognitive deficits in an AD animal model. This may represent a
potential mechanism underlying EA improvement of cognitive
deficits in AD.
In summary, the current study demonstrated that EA treat-
ment reduced Aβ production and BACE1 expression in the hip-
pocampus of SAMP8 mice, thus improving learning-memory
abilities. These novel findings suggest that EA treatment may
have the potential to block or delay the pathological progression
of AD.
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